Director-linked entities at LENZ Therapeutics (LENZ) granted 22,100 stock options

Rhea-AI Filing Summary

LENZ Therapeutics director-related entities received a new stock option award linked to board service. A stock option covering 22,100 shares of common stock was granted with an exercise price of $6.63 per share and an expiration date of June 15, 2036. The option vests 100% on the earlier of June 15, 2027 or the next annual stockholder meeting, provided the reporting person continues as an Outside Director. Under an arrangement with RA Capital Management, L.P., the option is held for the benefit of the RA Capital Healthcare Fund, the RA Capital Nexus Fund II, and a separately managed account, and the reporting person disclaims beneficial ownership because any net proceeds must be turned over to the adviser to offset advisory fees.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Scheiner Zachary

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	22,100	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 22,100 shares (Direct, null)

Footnotes (1)

1. Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), the RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying common stock.

Key Figures

Option grant size: 22,100 shares Exercise price: $6.63 per share Shares after transaction: 22,100 options +2 more

5 metrics

Option grant size 22,100 shares Stock option covering common stock

Exercise price $6.63 per share Stock option strike price

Shares after transaction 22,100 options Total derivative holdings following grant

Vesting date trigger Earlier of June 15, 2027 or next annual meeting Full vesting if Outside Director role continues

Option expiration June 15, 2036 Final date to exercise the stock option

Key Terms

Stock Option (right to buy), Outside Director, beneficial ownership, advisory fees, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Outside Director financial

"Subject to the Reporting Person continuing to be an Outside Director"

beneficial ownership financial

"The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying common stock."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

advisory fees financial

"which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account"

Advisory fees are payments made to financial advisors or investment managers for guidance, portfolio management, or other services, typically charged as a fixed amount or a percentage of assets under management. They matter because they lower an investor’s net returns—like paying a mechanic to tune a car, you expect better performance, so investors weigh whether the cost is justified by higher returns, better risk control, or convenience.

separately managed account financial

"and a separately managed account (the "Account")."

A separately managed account (SMA) is a personalized investment portfolio owned by a single investor and run by a professional manager who buys and sells securities on that investor’s behalf. It matters to investors because an SMA offers tailored asset selection, tax handling, and transparency—like hiring a personal chef who prepares meals to your dietary needs rather than sharing a set menu—so you can align holdings with your goals and see exactly what you own.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scheiner Zachary

(Last) (First) (Middle)

C/O LENZ THERAPEUTICS, INC.

201 LOMAS SANTA FE DRIVE, SUITE 300

(Street)

SOLANA BEACH CALIFORNIA 92075

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LENZ Therapeutics, Inc. [ LENZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$6.63	06/15/2026		A		22,100		(1)	06/15/2036	Common Stock	22,100	$0	22,100	D(2)

Explanation of Responses:

1. Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders.

2. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), the RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying common stock.

Remarks:

	/s/ Daniel R. Chevallard, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did LENZ (LENZ) disclose in this insider Form 4 filing?

LENZ Therapeutics reported a grant of stock options covering 22,100 shares of common stock tied to Outside Director service. The grant is a compensation-related award, not an open-market stock purchase or sale, and is held for the benefit of RA Capital-managed investment vehicles.

How many LENZ Therapeutics shares are covered by the new option grant?

The stock option grant covers 22,100 shares of LENZ Therapeutics common stock. These shares can be purchased at an exercise price of $6.63 per share once the option vests, subject to the specified vesting conditions related to ongoing Outside Director service.

When do the LENZ director-related stock options vest and expire?

All 22,100 option shares vest on the earlier of June 15, 2027 or the next annual stockholder meeting, if Outside Director service continues. The option expires on June 15, 2036, giving a long exercise window after vesting, consistent with typical director equity awards.

Who ultimately benefits from the LENZ stock option reported by Zachary Scheiner?

The option is held for the benefit of RA Capital Healthcare Fund, RA Capital Nexus Fund II, and a separately managed account. Under an arrangement with RA Capital Management, Zachary Scheiner must turn over any net cash or stock received, and he disclaims beneficial ownership.

Is the LENZ Form 4 transaction a stock purchase or sale in the market?

No, the Form 4 describes a stock option grant as compensation, not a market trade. The transaction is coded as an acquisition (grant/award), with a $6.63 exercise price and vesting based on continued Outside Director service, rather than an open-market buy or sell.

What is the exercise price on the LENZ Therapeutics stock option grant?

The stock option has an exercise price of $6.63 per share for 22,100 underlying common shares. This means the benefiting RA Capital-managed vehicles may purchase LENZ Therapeutics shares at $6.63 once the option has vested and before its June 15, 2036 expiration.